PTPI vs. ORGS, TCRT, VBIV, NERV, GLYC, TNXP, GLTO, FLGC, NRSN, and KTRA
Should you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Orgenesis (ORGS), Alaunos Therapeutics (TCRT), VBI Vaccines (VBIV), Minerva Neurosciences (NERV), GlycoMimetics (GLYC), Tonix Pharmaceuticals (TNXP), Galecto (GLTO), Flora Growth (FLGC), NeuroSense Therapeutics (NRSN), and Kintara Therapeutics (KTRA). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment.
Petros Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 551.25%. Given Orgenesis' higher probable upside, analysts clearly believe Petros Pharmaceuticals is more favorable than Orgenesis.
Orgenesis and Petros Pharmaceuticals both received 1 outperform votes by MarketBeat users.
Orgenesis has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500.
In the previous week, Petros Pharmaceuticals had 1 more articles in the media than Orgenesis. MarketBeat recorded 3 mentions for Petros Pharmaceuticals and 2 mentions for Orgenesis. Petros Pharmaceuticals' average media sentiment score of 1.88 beat Orgenesis' score of 1.64 indicating that Orgenesis is being referred to more favorably in the media.
Petros Pharmaceuticals has a net margin of -181.87% compared to Petros Pharmaceuticals' net margin of -1,343.97%. Orgenesis' return on equity of -102.32% beat Petros Pharmaceuticals' return on equity.
Petros Pharmaceuticals has higher revenue and earnings than Orgenesis.
22.6% of Orgenesis shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 5.7% of Orgenesis shares are held by company insiders. Comparatively, 36.4% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Petros Pharmaceuticals beats Orgenesis on 10 of the 13 factors compared between the two stocks.
Get Petros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Petros Pharmaceuticals Competitors List
Related Companies and Tools
